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Objective: To investigate the correlations between aqueous concentrations of interleukin 1β, 6, 8, 10, 12p (IL-1β, IL-6,
IL-8, IL-10, IL-12p), and tumor necrosis factor α (TNF-α) and the parameters of macular edema acquired by optical
coherence tomography (OCT) in patients with choroidal neovascularization.
Methods: IL-1β, IL-6, IL-8, IL-10, IL-12p, and TNF-α in the aqueous humor samples of 17 patients with exudative age-
related macular degeneration (AMD), ten patients with pathological myopia (PM), seven patients with idiopathic choroidal
neovascularization (CNV), and 14 patients with cataract and idiopathic epiretinal membrane or macular hole in the control
group were measured with cytometric bead array. The maximum macular thickness and macular volume within 1 mm, 3
mm, and 6 mm were measured with OCT.
Results: In the CNV groups, the aqueous levels of IL-6 and IL-8 were significantly associated with macular volume within
6 mm (p=0.011, p=0.008, respectively), while IL-1β, IL-10, IL-12p, and TNF-α showed no significant correlation with
either the maximum macular thickness or the macular volume. By further selecting patients with CNV who had accepted
their last intravitreal injection of bevacizumab within 3 months, the level of IL-6 still significantly correlated with the
maximum macular thickness (p=0.019) and macular volume within 1 mm (p=0.018), 3 mm (p=0.018), and 6 mm
(p=0.022). In patients with exudative AMD, the level of IL-6 was significantly associated with the maximum macular
thickness (p=0.025) and macular volume within 1 mm (p=0.025), 3 mm (p=0.006), and 6 mm (p=0.002). The aqueous
level of all cytokines did not vary significantly between the CNV patients who had accepted their last intravitreal injection
of bevacizumab within 3 months and the other patients, nor was a difference found among patients with exudative AMD,
PM, and idiopathic CNV, and the control group.
Conclusions: Intraocular concentrations of IL-6 and IL-8 (particularly IL-6) are significantly associated with the volume
of macular edema in patients with CNV. However, intravitreal injection of antivascular endothelial growth factor drugs
did not change the intraocular level of these inflammation cytokines.
Choroidal neovascularization (CNV), either idiopathic
CNV [1], exudative age-related macular degeneration (AMD)
[2], or secondary to pathological myopia (PM) [3], is one of
the main causes of vision impairment throughout the world.
Vascular  endothelial  growth  factor  (VEGF),  first
discovered as a vasopermeability factor [4], has been reported
to be associated with CNV. Many clinical trials have showed
encouraging  outcomes  for  intravitreal  injections  of  anti-
VEGF drugs for managing CNV [5-7]. Some authors even
recommend anti-VEGF as first-line treatment for some types
of  CNV  [8-10].  However,  in  addition  to  anti-VEGF
pharmacotherapy,  intravitreal  administered  anti-
inflammatory  substances,  such  as  triamcinolone  acetonide
(TA)  [11-13],  a  widely  used  anti-inflammatory  drug,  and
infliximab [14], an antibody of tumor necrosis factor α (TNF-
α),  have  also  shown  positive  effects  in  treating  CNV  in
patients and animal models. Therefore, in the era of anti-
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VEGF,  one  may  postulate  that  investigating  the  role  of
inflammatory factors in the development of CNV has become
more prominent.
In this study, we explored the relationship between levels
of inflammatory cytokines in aqueous humor of patients with
CNV after and not after recent anti-VEGF therapy and the
parameters of the macula acquired with optical coherence
tomography (OCT).
METHODS
This  study  included  17  patients  (17  eyes)  with  exudative
AMD, ten patients (ten eyes) with pathological myopia (PM),
seven  patients  (seven  eyes)  with  idiopathic  choroidal
neovascularization  (CNV)  who  underwent  intravitreal
injection  of  bevacizumab  (Avastin,  Genentech  Inc.,  San
Francisco, CA) as the study group, and 14 patients (14 eyes)
with cataract and idiopathic epiretinal membrane or a macular
hole  who  underwent  combined  cataract  and  vitrectomy
surgery  (CCVS)  as  the  control  group.  The  patients  were
consecutive in each group. The inclusion criterion in the study
group was the presence of active CNV. Exclusion criteria
included  glaucoma,  previous  photodynamic  therapy,  and
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574other retinal diseases, such as diabetic retinopathy and retinal
vascular occlusion.
All  patients  underwent  an  ophthalmic  examination
including  best-corrected  visual  acuity  (BCVA)  recording
using manifest refraction and the logMAR visual acuity chart,
non-contact tonometry, slit lamp assisted biomicroscopy of
the anterior segment and posterior segment of the eye, fundus
fluorescein angiography (FFA), and OCT (Optovue OCT-IV,
Optovue Inc., Fremont, CA). All patients in the study group
showed leakage on fluorescein angiographies (active CNV),
and they were further divided into two subgroups according
to  the  interval  between  the  last  intravitreal  injection  of
bevacizumab (IVB) and this time (>3 month group, more than
3 months, or <3 month group, less than 3 months). OCT was
analyzed  by  one  investigator,  and  the  maximum  macular
thickness and macular volume within 1 mm, 3 mm, and 6 mm
were  measured  using  built-in  software.  The  OCT
measurements  were  converted  from  millimeters  to
proportionally corresponding micrometers.
Aqueous  humor  was  collected  during  intravitreal
injection  or  CCVS.  All  procedures  conformed  to  the
Declaration  of  Helsinki  for  research  involving  human
subjects. Informed consent was obtained from all participants.
Undiluted  aqueous  humor  samples  (100–200  µl)  were
obtained  through  anterior  chamber  paracentesis.  All
injections and sample collections were performed using a
standard  sterilization  procedure  that  included  the  use  of
topical  povidone-iodine  and  levofloxacin  drops.  Samples
were stored in a sterilized plastic Corning (2 ml, Corning Inc.,
NY) at −70 °C until use.
The concentration of aqueous interleukin 1β, 6, 8, 10, 12p
(IL-1β, IL-6, IL-8, IL-10, IL-12p) and TNF-α were measured
with cytometric bead array (CBA), a method for capturing a
soluble analyte or set of analytes with beads of known size
and fluorescence, making it possible to detect analytes using
flow cytometry. Each capture bead has been conjugated with
a specified antibody. The detection reagent is a mixture of
phycoerythrin (PE)-conjugated antibodies, which provides a
fluorescent  signal  in  proportion  to  the  amount  of  bound
analyte.  When  capture  beads  and  detector  reagent  are
incubated with an unknown sample containing recognized
analytes,  sandwich  complexes  (capture  bead+analyte
+detection reagent) are formed that can be measured using
flow cytometry (BD FACSCalibur, BD Bioscience, San Jose,
CA) to identify particles with the fluorescence characteristics
of the bead and detector. Six bead population with distinct
fluorescence  intensities  coated  with  specific  capture
antibodies for IL-1β, IL-6, IL-8, IL-10, IL-12p, and TNF-α
were  mixed  together  to  form  the  bead  array.  Thus,  the
concentration of each cytokine in one unknown sample can
be calculated from regressive analysis of the standard curve
simultaneously. In this study, 50  μl of undiluted aqueous
humor  sample  was  used  for  each  test.  Quality  control
procedures  were  performed  according  to  the  CBA  kit
instructions.
The  Pearson  correlation  test  was  used  to  explore  the
relationship between the aqueous level of a cytokine and the
OCT  parameters  (Statistical  Package  for  Social  Sciences
[SPSS],  ver.  17.0;  SPSS,  Chicago,  IL).  Parameters  were
compared  using  the  Mann–Whitney  U  test  between  two
groups and the Kruskal–Wallis H test to compare variables
among various groups. The chi-square test and the Fisher
exact t test were used to compare noncontinuous variables.
Values  were  reported  as  mean±standard  deviation  (SD).
Statistical significance was set at p<0.05 for two-tail analysis.
RESULTS
A total of 48 aqueous humor samples from 48 patients were
collected (Table 1). The age of AMD and control group was
significantly older than the other two groups (p<0.001), while
gender, BCVA and IOP did not significantly vary among
groups (all p>0.05).
In the CNV group, the aqueous levels of IL-6 and IL-8
were significantly associated with macular volume within
6 mm (PIL-6=0.011, R2=0.176, PIL-8=0.008, R2=0.187; Table 2),
while IL-1β, IL-10, IL-12p, and TNF-α showed no significant
correlation with the maximum macular thickness or macular
volume within 1 mm, 3 mm, or 6 mm (all p>0.05). Moreover,
in the CNV group who had accepted their last IVB within the
last  3  months  (<3  months),  the  level  of  IL-6  correlated
significantly  with  the  maximum  macular  thickness  and
macular volume within 1 mm (p=0.019, R2=0.382), 3 mm
TABLE 1. COMPOSITION OF THE STUDY POPULATION (MEAN±SD).
  Control Exudative AMD PM Idiopathic CNV p-value
Number 14 17 10 7  
Age (years) 62.4±14.5 68.6±12 49.4±10 33.7±10.4 <0.001*
Female-no (%) 11 (79%) 5 (29.4%) 5(50%) 4 (57%) 0.057**
BCVA 0.2±0.13 0.24±0.19 0.20±0.23 0.36±0.36 0.787*
IOP (mmHg) 14.3±2.6 13.6±3.0 12.3±2.6 14.86±3.08 0.313*
        *Kruskal–Wallis H test, compared among control group, exudative AMD, PM and idiopathic CNV groups. **Fisher’s exact t-
        test, compared among control group, exudative AMD, PM and idiopathic CNV groups. AMD, age-related macular degeneration;
        PM, pathological myopia; CNV, choroidal neovascularization; BCVA, best corrected visual acuity; IOP, intraocular pressure.
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576(p=0.018, R2=0.382), and 6 mm (p=0.022, R2=0.366; Table 2,
Figure 1). However, in the CNV group who had accepted their
last IVB more than 3 months before or never (>3 months), no
significant  correlation  was  found  between  the  cytokine
concentrations and the macular parameters (all p>0.05).
In exudative AMD (Table 3), the level of IL-6 was also
significantly associated with the maximum macular thickness
(p=0.025,  R2=0.258)  and  macular  volume  within  1  mm
(p=0.025, R2=0.258), 3 mm (p=0.006, R2=0.386), and 6 mm
(p=0.002, R2=0.461).
The aqueous level of all cytokines investigated in this
study showed no significant difference between the patients
with CNV who had accepted their last IVB within the last 3
months (<3 months), patients with CNV who had accepted
their  last  IVB  more  than  3  months  before  or  never  (>3
months),  and  the  control  group  (all  p>0.05,  Table  4).
Moreover, no difference was found among the patients with
exudative AMD, PM, and idiopathic CNV compared to the
control group, either (all p>0.05, Table 4).
DISCUSSION
Although CNV is not a classic inflammatory disease like
uveitis, much evidence from anatomic studies [15,16] and
molecular experiments [17-19] has supported the hypothesis
that  inflammation  plays  an  important  role  in  disease
pathogenesis  and  progression.  Innate  immunity  and
autoimmune components are believed to be heavily involved
in  CNV  development.  Macrophage,  lymphocytes,  and
neutrophils have been found to be important in animal models
Figure 1. Interleukin (IL)-6 associated
significantly  with  maximum  macular
thickness (p=0.019, R2=0.381), volume
of  macula  within  1  mm  (p=0.018,
R2=0.382), 3 mm (p=0.018, R2=0.382)
and  6  mm  (p=0.022,  R2=0.366)  in
choroidal  neovascularization  (CNV)
group  who  accepted  IVB  within  3
months.
TABLE 3. P VALUES OF EACH PEARSON CORRELATION TEST BETWEEN LEVEL OF CYTOKINES AND OCT PARAMETERS IN EXUDATIVE
AMD.
Cytokines MMT MV (1 mm) MV (3 mm) MV (6 mm)
IL-1b 0.730 0.730 0.888 0.922
IL-6 0.025* 0.025* 0.006* 0.002*
IL-8 0.150 0.152 0.110 0.087
IL-10 0.306 0.309 0.174 0.092
IL-12p 0.535 0.534 0.588 0.408
TNF-α 0.123 0.122 0.2414 0.128
               MMT, maximum macular thickness; MV, volume of macula; IL, interleukin; TNF, tumor necrosis factor.
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577and CNV patients [20-22]. IL-6 is a cytokine derived from
activated T lymphocytes with multiple functions, including
induction of B-cell growth, induction of B-cell differentiation
and  antibody  production,  induction  of  differentiation  and
proliferation of T cells, synergistic induction with IL-3 of
hematopoietic  cell  growth,  and  induction  of  hepatocyte
secretion of acute-phase inflammatory proteins [23,24]. IL-8
is a group of peptides produced by various types of cell, which
activate and recruit polymorphonuclear leukocytes in acute
and chronic inflammatory process, and are probably involved
in initiating labor and delivery in pregnant women [25,26].
Both were found elevated in the synovial fluid of patients who
had rheumatoid arthritis. This evidence suggested the role of
cytokines in inflammatory diseases [27].
Our results indicated that the aqueous level of IL-6 and
IL-8 was significantly associated with the macular volume
within 6 mm in patients with CNV, and the aqueous level of
IL-6 was significantly associated with the maximum macular
thickness and macular volume within 1 mm, 3 mm, and 6 mm
in patients who had received IVB within the last 3 months.
This implied that IL-6 and IL-8, especially IL-6, not only
participate in the process of CNV but also may be another
target molecule in treating idiopathic CNV, exudative AMD,
and CNV secondary to PM. Furthermore, a macular volume
within 6 mm could also be an indicator of the aqueous level
of these cytokines in the follow-up process, especially for
patients who had accepted IVB within the last 3 months. We
also  found  that  the  concentration  of  IL-6  had  a  linear
correlation with the maximum height of macula and macular
volume within 1 mm, 3 mm, and 6 mm in exudative AMD.
Thus, anti-IL-6 therapy may be further considered in this anti-
VEGF era.
Our  results  also  suggested  that  the  aqueous  level  of
cytokines investigated in this study did not significantly vary
between patients with CNV who had undergone IVB within
the last 3 months and the other patients with CNV. This may
explain  why  some  patients  were  resistant  to  anti-VEGF
therapy.  IVB  could  downregulate  only  the  VEGF
concentration, not other cytokines such as IL-6 and IL-8. Anti-
inflammatory agents may still be necessary for those patients
after failed anti-VEGF therapy.
We could not find any significant correlation between the
concentrations of IL-1β, IL-10, IL-12p, and TNF-α and any
OCT parameters in any group in this study, which suggested
that their role in the progress of CNV may be not as pivotal
as that of anti-IL-6 and anti-IL-8.
Our  results  were  in  agreement  with  several  previous
studies.  Higgins  [28]  found  that  the  response  to  reactive
oxygen  species  in  the  photoreceptor  outer  segments  of
inflammatory injury, commonly believed to be an initiation
of AMD, could lead to increased expression and secretion of
IL-8. Goverdhan [29] also suggested that the −251A allele
(rs4073) of the IL-8 promoter is more prevalent in AMD cases
than controls. Izumi-Nagai et al. [30] found that the IL-6
receptor  mediated  activation  of  the  signal  transducer  and
activator of transcription-3 promotes CNV generation and the
IL-6  receptor  blockade  could  inhibit  in  vivo  and  in  vitro
expression  of  inflammation-related  molecules  such  as
monocyte  chemotactic  protein,  intercellular  adhesion
molecule-1, VEGF, and macrophage infiltration, which then
could be a therapeutic strategy to suppress CNV-associated
AMD.
There were limitations in this study. First, the selection
of the control group may have caused selection bias, since the
aqueous level of all cytokines investigated in this study did
not vary significantly between the CNV group and the control
group  (all  p>0.05).  Patients  with  idiopathic  epiretinal
membrane  or  a  macular  hole  [31-35]  were  the  preferred
control in most previous cytokine research of fundus diseases.
However, a slight inflammation process may also potentially
be  involved  in  the  formation  of  idiopathic  epiretinal
membrane  or  a  macular  hole;  therefore,  we  have  to
acknowledge  that  the  aqueous  level  of  all  the  cytokines
investigated in this study of patients with CNV may possibly
differ from that of normal cataract patients without epiretinal
membrane or a macular hole. Further study will be conducted
to evaluate this issue. Second, the number of enrolled patients
was  not  large,  which  may  cover  some  minor  significant
association between factors. With a larger number of study
TABLE 4. LEVELS OF CYTOKINES IN CNV AND CONTROL GROUP (MEAN±SD).
Cytokines <3 mon >3 mon Control P* Exudative AMD PM Idiopathic CNV p*
IL-1b 1.98±0.28 1.99±0.23 1.94±0.20 0.672 2.1±0.3 1.9±0.2 2.0±0.2 0.287
IL-6 3.94±2.37 4.49±3.09 4.47±2.07 0.610 3.6±1.8 4.9±2.0 3.1±1.5 0.124
IL-8 4.18±1.22 5.52±2.59 5.51±2.90 0.118 4.5±1.5 4.9±0.8 4.3±1.0 0.145
IL-10 1.82±0.23 1.85±0.25 1.90±0.17 0.257 1.8±0.3 1.9±0.1 1.8±0.3 0.258
IL-12p 2.08±0.19 2.19±0.31 2.19±0.27 0.444 2.2±0.3 2.2±0.2 2.1±0.3 0.755
TNF-α 1.90±0.22 1.85±0.27 1.95±0.28 0.507 1.9±0.2 1.8±0.2 2.0±0.4 0.621
        *Kruskal–Wallis H test was used. CNV, choroidal neovascularization group; <3mon, patients who receive last IVB within 3
        months; >3mon, patients who receive last IVB for more than 3 months and never; Control, patients with cataract and idiopathic
        epiretinal membrane or macular hole who underwent combined cataract and vitrectomy surgery; AMD, age-related macular
        degeneration; PM, pathological myopia; CNV, choroidal neovascularization; IL, interleukin; TNF, tumor necrosis factor.
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578participants,  the  correlations  between  the  aqueous
concentrations of the cytokines and the macular thickness or
macular volume may become statistically significant. Third,
only six cytokines were detected in this study, which fail to
represent the main pathological mechanism involved in the
development of CNV. Fourth, the aqueous humor samples
may be not as valuable as vitreous fluid for detecting cytokine
concentrations  for  fundus  diseases.  However,  obtaining
vitreous samples needs to expand the surgical intervention
while CNV was not the surgical indication of vitrectomy for
most cases.
A  previous  study  investigated  the  relationship  of
recurrent CNV and cytokines, but this study may be the first
one that states the association between cytokines and CNV
volume,  suggesting  their  importance.  In  conclusion,  the
aqueous level of IL-6 is positively related to the maximum
macular thickness and macular volume within 1 mm, 3 mm,
and 6 mm in patients with CNV who had undergone their last
IVB within the last 3 months. Intravitreal injection of anti-
VEGF  drugs  did  not  change  the  intraocular  level  of
inflammation cytokines, including IL-1β, IL-6, IL-8, IL-10,
IL-12p, and TNF-α. Furthermore, IL-6 is positively related to
these OCT parameters in exudative AMD. IL-6 and IL-8,
especially the former, may be additional target molecules in
therapy for CNV.
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